	US 11,793,177 B2
	Animal model of Angelman Syndrome
Edwin John Weeber, Apollo Beach, FL (US); David J. Segal, Davis, CA (US); Henriette O'Geen, Davis, CA (US); Benjamin Pyles, Davis, CA (US); and Scott V. Dindot, College Station, TX (US)
Assigned to UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
Appl. No. 16/330,871
Filed by UNIVERSITY OF SOUTH FLORIDA, Tampa, FL (US); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
PCT Filed Oct. 3, 2017, PCT No. PCT/US2017/054992 § 371(c)(1), (2) Date Mar. 6, 2019, PCT Pub. No. WO2018/067608, PCT Pub. Date Apr. 12, 2018.
Claims priority of provisional application 62/403,463, filed on Oct. 3, 2016.
Prior Publication US 2019/0208752 A1, Jul. 11, 2019
Int. Cl. A01K 67/027 (2006.01); C12N 9/10 (2006.01); A61K 49/00 (2006.01)

CPC A01K 67/0276 (2013.01) [A01K 67/027 (2013.01); A61K 49/0008 (2013.01); C12N 9/104 (2013.01); A01K 2217/054 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0356 (2013.01)]

10 Claims

1. A transgenic rat whose genome comprises a homozygous deletion of its endogenous E3 ubiquitin ligase (Ube3a) gene, wherein the transgenic rat does not express Ube3a and exhibits physiological and/or behavioral features associated with Angelman Syndrome.